Giulio joined IXICO as Chief Executive Office in February 2017. He has over 30 years of experience in the life science and diagnostic sectors and has led business operations ranging from £4M to £125M of revenues.
He was previously Managing Director of the Genomics division of the LGC group, the private equity owned international life science measurement and testing company. In addition to trebling revenues in under four years and completing three acquisitions in eighteen months, Giulio was a member of the executive leadership team responsible for the successful sale of LGC group to the leading private equity firm, KKR.
Guilio also held a variety of leadership positions across both the Life Science and Anatomical Pathology Divisions at ThermoFisher Scientific. These included Managing Director, Vice President Commercial Operations EMEA and APAC, with his final post being the Global Vice President and General Manager of the 1,200 employee Anatomical Pathology organisation.
His first eighteen years were spent in business development and divisional leadership roles with Dupont and Anachem.
Giulio holds a BSc from Cardiff University and an MBA (distinction) from Warwick University.
Derek is a founder and was CEO since IXICO’s incorporation in 2004 to 2017. As such, he has built IXICO into a profitable international business including taking the entrepreneurial leadership role in raising both equity and grant finance as well as in customer-facing activities.
He has been working on medical imaging science for over twenty-five years and has authored more than eighty journal papers in this field. He is a member of the MRI Core of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) in the US, has served on the scientific advisory board for several pharmaceutical companies and is involved in the US FDA Critical Path Institute’s Coalition Against Major Diseases (CAMD) biomarker qualification initiatives.
Derek has a PhD in medical image analysis at the Medical School of Guy's & St Thomas' Hospitals, University of London, an MSc in Medical Physics at University of Surrey and a BSc degree in Physics from Imperial College. He undertook business training at London Business School as part of the CSEL programme. He holds an academic appointment as full professor at University College London and was formerly a professor at King’s College London.
Susan joined IXICO as Chief Financial Officer in October 2014. She was previously Group Chief Financial Officer and a director of Novacyt SA, a European diagnostic company listed on the French Alternext exchange. Prior to that she was Chief Financial Officer and a director of Lab21 Group Limited which was acquired by Novacyt in June 2014.
Susan also held executive positions at BioWisdom Limited where she was Chief Financial Officer until its acquisition by Instem plc and Finance Director at RiboTargets Limited until its acquisition by Vernalis plc.
She has held senior financial management roles at other life science companies including Lonza Biologics, Celltech Group and Monsanto, gaining significant experience in growing businesses and corporate transactions.
SVP of Commercial Operations
John Hall is VP of Business Development and leads the Sales and Marketing Team at IXICO.
Since joining IXICO over four years ago John has played a key role in developing the company from a start-up into a major supplier of imaging solutions to the global pharmaceutical industry and academic community, and its expansion into health care.
Starting his career in Technology Transfer roles at Warwick University and King’s College London, John identified and developed commercial opportunities and spin-out companies such as Warwick Warp Limited – which under John’s leadership won the 2006 Research Councils Business Plan Competition.
An alumnus of the University of Manchester (BSc Biochemistry) John holds a PhD in Proteomics and Systems Biology from the University of Durham which was co-funded by Amersham Biosciences and in collaboration with the National Institute for Basic Biology, Japan.
SVP of Clinical Science
Dr Janet Munro joined IXICO as SVP of clinical science in December 2015 when Optimal Medicine was acquired by the company; Janet was founder and CEO of Optimal Medicine.
She qualified in medicine in London and practiced in psychiatry at the Maudsley Hospital London. She was Senior Lecturer at King’s College London (KCL) and in 2006 co-founded a personalised medicine spin-out company. She served as Director of Clinical Operations and a Board Director until acquisition in 2009. She then founded Optimal Medicine, a digital health company for mental health disorders. Fuelled by her clinical experience, Janet has a special interest in patient-centred technologies to optimise the treatment of CNS disorders. She has over fifty publications and has co-authored several chapters and books on personalised medicine. She holds an honorary post at the INSERM Mental Health Research Unit in Montpellier, France and a visiting appointment at KCL.
VP of Technology
Kate has an extensive background in the field of medical image analysis and has been with IXICO since 2005.
Her initial role was on the operational side, managing clinical trials across all phases and different disease areas. She then took over the development of IXICO's image management system, TrialTracker™, which is now used in all trials run by IXICO, by academic groups and in the diagnostic products. Kate now has a key role incorporating new analysis technology into new products and providing scientific oversight to all projects.
Kate took a BSc degree in Physics at Oxford University, an MSc in Medical Physics at Imperial College London, and a PhD in Medical Image Analysis at King's College London. Following her PhD, Kate continued in research for a few years before moving into a job co-ordinating large imaging studies in the academic sector, focused on brain imaging with MRI. Kate has also completed Project Management training and undertaken electives at the London Business School.
VP Digital Healthcare
Sylke Grootoonk joined IXICO in July 2015 as VP Digital Healthcare.
Sylke’s career spans twenty-five years in academic, industry and healthcare service provision settings. Her expertise covers both commercial and operational domains with a track record of managing rapid growth and market penetration. Before joining IXICO Sylke led the service development for diagnostic solutions in hospital and community settings at InHealth. She also led the improvement programme within a patient referral management centre for NHS England commissioned services. Along with her previous role heading up PETCT diagnostic services for Alliance Medical, this has given her extensive experience of the NHS and private healthcare market in the UK.
Sylke previously held positions at Siemens Healthcare as product specialist in Europe and marketing manager in the US. Her academic tenure was at the Hammersmith Hospital in London and at the Wellcome Trust Centre for Neuroimaging, where she completed an industry sponsored PhD in Medical Physics. Sylke graduated with distinction from the Imperial College Business School executive MBA programme in 2010.
VP of Healthcare Technology
Ken Tubman joined IXICO as VP of Healthcare Technology in December 2015.
Ken is a seasoned IT professional with a passion for enhancing the interface between healthcare and technology. With extensive experience in enterprise-level software development and information architecture, Ken has a strong interest in user experience. He specializes in developing solutions that address complex business and clinical problems with simplicity and efficiency; focusing on internal and industry standards, automation and reusable technology. Prior to joining IXICO, Ken served as CTO for Optimal Medicine (acquired by IXICO), a digital health company for mental health disorders.
Michelle Lax is the Vice President of Clinical Operations at IXICO, leading a team of project managers, image analysts, image scientists, and data managers. She joined IXICO in 2012.
Michelle studied Physics at the University of Nottingham before completing a Medical Physics and Clinical Engineering MSc at Sheffield University. On deciding to specialise in medical physics, Michelle completed the IPEM-sponsored 2 year program to obtain state registered clinical scientist status, and continued for 4 years working within the NHS as a nuclear medicine physicist.
In 2005, Michelle moved into industry to work as a Technology Project Manager at GE Healthcare, Medical Diagnostics, providing scientific strategic guidance on the development of PET, MRI, Optical, CT, and Ultrasound imaging agents, in global multicentre trials. Michelle excelled through the world renowned GE leadership program and adopted greater leadership and Project Director roles within clinical development.
In 2010, Michelle moved internally to Hammersmith Imanet PET centre to lead the PET operations team, managing out a down-sizing and decommissioning process, before moving back into MDx in a commercial role as New Business Manager EMEA.